EP1567182A4 - Verhinderung der desensibilisierung vonrezeptoren - Google Patents

Verhinderung der desensibilisierung vonrezeptoren

Info

Publication number
EP1567182A4
EP1567182A4 EP03777526A EP03777526A EP1567182A4 EP 1567182 A4 EP1567182 A4 EP 1567182A4 EP 03777526 A EP03777526 A EP 03777526A EP 03777526 A EP03777526 A EP 03777526A EP 1567182 A4 EP1567182 A4 EP 1567182A4
Authority
EP
European Patent Office
Prior art keywords
receptors
preventing desensitization
desensitization
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03777526A
Other languages
English (en)
French (fr)
Other versions
EP1567182A2 (de
Inventor
Jonathan S Stamler
Robert J Lefkowitz
Erin J Whalen
Walter J Koch
Claude A Piantadosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of EP1567182A2 publication Critical patent/EP1567182A2/de
Publication of EP1567182A4 publication Critical patent/EP1567182A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP03777526A 2002-10-25 2003-10-20 Verhinderung der desensibilisierung vonrezeptoren Withdrawn EP1567182A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US280085 1999-03-29
US10/280,085 US6627602B2 (en) 2001-11-13 2002-10-25 Preventing desensitization of receptors
PCT/US2003/029134 WO2004039313A2 (en) 2002-10-25 2003-10-20 Preventing desensitization of receptors

Publications (2)

Publication Number Publication Date
EP1567182A2 EP1567182A2 (de) 2005-08-31
EP1567182A4 true EP1567182A4 (de) 2010-09-08

Family

ID=32228743

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03777526A Withdrawn EP1567182A4 (de) 2002-10-25 2003-10-20 Verhinderung der desensibilisierung vonrezeptoren

Country Status (6)

Country Link
US (3) US6627602B2 (de)
EP (1) EP1567182A4 (de)
JP (2) JP4705783B2 (de)
AU (1) AU2003287006B2 (de)
CA (1) CA2503624A1 (de)
WO (1) WO2004039313A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627738B2 (en) * 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
JP4194364B2 (ja) * 2000-10-16 2008-12-10 デューク・ユニバーシティ 嚢胞性繊維症におけるエアロゾル化されたｓ−ニトロソグルタチオンの治療的使用
AU2002224466A1 (en) * 2000-10-31 2002-05-15 Duke University Hypotension
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
GB0326047D0 (en) * 2003-11-07 2003-12-10 Univ Sheffield Substance
JP2007533668A (ja) * 2004-04-23 2007-11-22 ノーザン シドニー アンド セントラル コースト エリア ヘルス サービス 心筋の病気を治療するための方法および組成物
EP3556401A1 (de) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
JP2008303145A (ja) * 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
FR2914554B1 (fr) * 2007-04-05 2009-07-17 Germitec Soc Par Actions Simpl Procede de suivi de l'uitilisation d'un appareil medical.
WO2010042546A1 (en) 2008-10-06 2010-04-15 Indiana University Research And Technology Corporation Methods and apparatus for active or passive assistance in the circulatory system
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
BR112012008508A2 (pt) * 2009-10-13 2017-06-13 Novan Inc revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2681286B1 (de) 2011-02-28 2018-08-15 Novan, Inc. Stickoxid-freisetzende s-nitrosothiol-modifizierte kieselsäureteilchen und verfahren zu ihrer herstellung
CN111701010B (zh) * 2016-05-27 2023-09-26 益普生生物制药有限公司 用色氨酸或酪氨酸稳定的液体神经毒素制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033823A1 (en) * 1997-12-23 1999-07-08 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
WO2000012075A1 (en) * 1998-09-01 2000-03-09 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
WO2001017596A1 (en) * 1999-09-08 2001-03-15 Duke University Method of treating cardio pulmonary diseases with no group compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476108A (en) * 1981-01-16 1984-10-09 Kessler Jack H Bactericidal method
JPS63208525A (ja) * 1987-02-25 1988-08-30 Kikkoman Corp 心不全治療剤
DE69127756T2 (de) * 1990-12-05 1998-02-05 Gen Hospital Corp Verwendung von no zur behandlung oder prävention der bronchokonstriktion
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor
US5985862A (en) * 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
DE69823211T2 (de) * 1997-02-06 2004-08-26 Duke University No-modifizierte Hämoglobine und Verwendung dafür
JP4777489B2 (ja) * 1997-03-31 2011-09-21 ザ チルドレンズ メディカル センター コーポレーション アポトーシス性酵素を不活性化するためのニトロシル化
US6617355B1 (en) * 1997-05-21 2003-09-09 The University Of Virginia Patent Foundation Treating asthma by preventing and/or accomodating S-nitrosothiol breakdown
US6486206B1 (en) * 1997-09-29 2002-11-26 Cprx Inc. Mechanical and pharmacologic therapies to treat cardiac arrest
CA2306096A1 (en) * 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
CA2348741C (en) * 1998-10-30 2010-04-20 Nitromed Inc. Nitrosasted and nitrosylated nonsteroidal antiinflammatory compounds, comositions and methods of use
US7045152B2 (en) * 1999-09-08 2006-05-16 Duke University Treating pulmonary disorders with gaseous agent causing repletion of GSNO
JP2004501143A (ja) * 2000-06-22 2004-01-15 ニトロメド　インコーポレーテッド ニトロソ化およびニトロシル化タキサン、組成物および使用方法
JP4194364B2 (ja) * 2000-10-16 2008-12-10 デューク・ユニバーシティ 嚢胞性繊維症におけるエアロゾル化されたｓ−ニトロソグルタチオンの治療的使用
US6359182B1 (en) 2000-10-26 2002-03-19 Duke University C-nitroso compounds and use thereof
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US6489206B2 (en) * 2001-03-22 2002-12-03 United Microelectronics Corp. Method for forming self-aligned local-halo metal-oxide-semiconductor device
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
US6472390B1 (en) 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033823A1 (en) * 1997-12-23 1999-07-08 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
WO2000012075A1 (en) * 1998-09-01 2000-03-09 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
WO2001017596A1 (en) * 1999-09-08 2001-03-15 Duke University Method of treating cardio pulmonary diseases with no group compounds

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
9 STEVENSON LW ET AL: "cardiac Tailored Therapy Using Dobutamine and Nitroglycerin in Advanced Heart Failure", J AM COLL CARDIOL AM J CARDIOL J AM COLL CARDIOL, 1 January 1990 (1990-01-01), pages 174 - 180617, XP055174253, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S0002914999004749/pdfft?md5=cee8d57b815068577317983c658c2ec1&pid=1-s2.0-S0002914999004749-main.pdf> [retrieved on 20150305] *
CAPOMOLLA S ET AL: "Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome.", EUROPEAN JOURNAL OF HEART FAILURE : JOURNAL OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY OCT 2001 LNKD- PUBMED:11595609, vol. 3, no. 5, October 2001 (2001-10-01), pages 601 - 610, XP002593435, ISSN: 1388-9842 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2001, ARONOW W S: "Drug treatment of elderly patients with acute myocardial infarction: practical recommendations.", XP002593431, Database accession no. NLM11772121 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 1990 (1990-01-01), FIRTH B G ET AL: "Survival in congestive heart failure: have we made a difference?", XP002593432, Database accession no. NLM2195883 *
DRUGS & AGING 2001 LNKD- PUBMED:11772121, vol. 18, no. 11, 2001, pages 807 - 818, ISSN: 1170-229X *
GEORG NOLL: "Activity of the L-arginine/nitric oxide pathway and endothelin-1 in experimental heart failure", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (1994), 23(6),, 1 January 1994 (1994-01-01), pages 916 - 921, XP055174146, Retrieved from the Internet <URL:http://pdfs.journals.lww.com/cardiovascularpharm/1994/06000/Activity_of_the_L_Arginine_Nitric_Oxide_Pathway.9.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1425559145929;payload|mY8D3u1TCCsNvP5E421JYPPlNl9ZUXrQDsjmMHeXqBgfxP56d5BAis WhfSrPR1S6lcHrAT5WTvTkrI7Jc1zUq2UlEn8N1x7qr2heZXbSZE2/LnQkUnb> [retrieved on 20150305] *
KIELER-JENSEN N ET AL: "A comparison of prostacyclin and sodium nitroprusside for the treatment of heart failure after cardiac surgery.", JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA DEC 1995 LNKD- PUBMED:8664453, vol. 9, no. 6, December 1995 (1995-12-01), pages 641 - 646, XP002593436, ISSN: 1053-0770 *
LI, LIHUI: "Combined sodium nitroprusside , dobutamine and magnesium sulfate in treatment of refractory heart", HUNAN YIXUE , 13(5), 293-294 CODEN: HUYIER; ISSN: 1001-9421, 1996 *
LU, GUOQING: "Nitroglycerol, dobutamine , and furosemide combined treatment of refractory congestive heart failure", SHANXI YIYAO ZAZHI , 27(1), 11 CODEN: SIYCDB; ISSN: 0253-9926, 1998 *
MARK H DRAZNER ET AL: "Tailored therapy using dobutamine and nitroglycerin in advanced heart failure", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 84, no. 8, 1 October 1999 (1999-10-01), pages 941 - 943, XP055174318, ISSN: 0002-9149, DOI: 10.1016/S0002-9149(99)00474-9 *
MAYERS I ET AL: "Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by s-nitrosoglutathione.", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY MAY 1999 LNKD- PUBMED:10220697, vol. 117, no. 5, May 1999 (1999-05-01), pages 1009 - 1016, XP002593434, ISSN: 0022-5223 *
SARKAR D ET AL: "Positive inotropic effects of NO donors in isolated guinea-pig and human cardiomyocytes independent of NO species and cyclic nucleotides.", CARDIOVASCULAR RESEARCH DEC 2000 LNKD- PUBMED:11090838, vol. 48, no. 3, December 2000 (2000-12-01), pages 430 - 439, XP002593430, ISSN: 0008-6363 *
SATYA P. VERMA,: "Modulation of inotropic therapy by venodilation in acute heart failure : a randomized comparison of four inotropic agents, alone and combined with isosorbide dinitrate", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (1992), 19(1),, 1 January 1992 (1992-01-01), pages 24 - 33, XP055174117, Retrieved from the Internet <URL:http://pdfs.journals.lww.com/cardiovascularpharm/1992/01000/Modulation_of_Inotropic_Therapy_by_Venodilation_in.4.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1425555743488;payload|mY8D3u1TCCsNvP5E421JYPPlNl9ZUXrQDsjmMHeXqBgfxP56d5BAis WhfSrPR1S6lcHrAT5WTvTkrI7Jc1zUq2UlEn8N1x7qr2heZXbSZE2/LnQk> [retrieved on 20150305] *
See also references of WO2004039313A2 *
SOGO N ET AL: "S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery.", BRITISH JOURNAL OF PHARMACOLOGY NOV 2000 LNKD- PUBMED:11082133, vol. 131, no. 6, November 2000 (2000-11-01), pages 1236 - 1244, XP002593433, ISSN: 0007-1188 *
THE AMERICAN JOURNAL OF MEDICINE JAN 1990 LNKD- PUBMED:2195883, vol. 88, no. 1N, January 1990 (1990-01-01), pages 3N - 8N, ISSN: 0002-9343 *
ZAMAN KHALEQUZ ET AL: "S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1006/BBRC.2001.4935, vol. 284, no. 1, 1 June 2001 (2001-06-01), pages 65 - 70, XP002360446, ISSN: 0006-291X *

Also Published As

Publication number Publication date
AU2003287006B2 (en) 2010-03-18
US20040053852A1 (en) 2004-03-18
US20030092633A1 (en) 2003-05-15
EP1567182A2 (de) 2005-08-31
US6627602B2 (en) 2003-09-30
WO2004039313A3 (en) 2004-07-22
JP2010159307A (ja) 2010-07-22
AU2003287006A1 (en) 2004-05-25
US6964984B2 (en) 2005-11-15
CA2503624A1 (en) 2004-05-13
US20060100159A1 (en) 2006-05-11
JP2006503901A (ja) 2006-02-02
JP4705783B2 (ja) 2011-06-22
WO2004039313A2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003286263A8 (en) Complexes of receptors
AU2003275128A8 (en) Isolation and use of ryanodine receptors
EG23458A (en) Set of elements for assemlying structures
EP1567182A4 (de) Verhinderung der desensibilisierung vonrezeptoren
AU2003279841A8 (en) Uses of human zven antagonists
GB0226227D0 (en) Receptors
IL163696A0 (en) Hfa-suspension formulation of an anhydrate
AU2003262141A8 (en) Preperation of desloratatine
GB0223399D0 (en) Receptors
AU2003300867A8 (en) Uses of the snorf207 receptor
PL356853A1 (en) Application of bacteriphages
TW551198U (en) Safety structure of oval device
HUP0203929D0 (en) New use of substituted alkyl-piridazinone derivatives
AU2003219424A1 (en) Methods of using alpha 1b-adrenergic receptors
GB0228112D0 (en) Receptors
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
PL373284A1 (en) Analogues of vitamin d
TW566199U (en) Structure of earplug
TW567775U (en) Structure of hairtie
TW534271U (en) Improved structure of lighting device
AU2003242688A1 (en) Inhibition of nuclear receptors
TW533774U (en) Structure improvement of flyswatter
TW590198U (en) Structure of lighting device
EP1579866A4 (de) Neue verwendung von edg-rezeptoren
TW547548U (en) Improved structure of anti-thieving devices

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050525

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PIANTADOSI, CLAUDE, A.

Inventor name: KOCH, WALTER, J.

Inventor name: WHALEN, ERIN, J.

Inventor name: LEFKOWITZ, ROBERT, J.

Inventor name: STAMLER, JONATHAN, S.

A4 Supplementary search report drawn up and despatched

Effective date: 20100806

17Q First examination report despatched

Effective date: 20110110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150922